Innovating Obesity Drug Discovery: Trends, Challenges, and Translational Strategies
Supported by:
8 October 2025
3:00pm
Shares
- Like
- Digg
- Del
- Tumblr
- VKontakte
- Buffer
- Love This
- Odnoklassniki
- Meneame
- Blogger
- Amazon
- Yahoo Mail
- Gmail
- AOL
- Newsvine
- HackerNews
- Evernote
- MySpace
- Mail.ru
- Viadeo
- Line
- Comments
- Yummly
- SMS
- Viber
- Telegram
- Subscribe
- Skype
- Facebook Messenger
- Kakao
- LiveJournal
- Yammer
- Edgar
- Fintel
- Mix
- Instapaper
- Copy Link
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk.
Obesity is a complex, multifactorial disease that presents major hurdles for drug discovery and development. While advances in incretin-based therapies and novel metabolic targets have made progress, translating early discoveries into safe, effective, and lasting treatments remains a significant challenge.
In this webinar, hear from Andrew Grottick and Luke Oostdyk of Eurofins Discovery as they examine the evolving landscape of obesity drug discovery – focusing on emerging scientific trends, unmet medical needs, and key translational challenges. They will also discuss how integrated strategies – spanning target validation, in vitro biology, medicinal chemistry, ADME/PK, and in vivo efficacy models – can accelerate development and reduce risk across the discovery pipeline.
Through real-world case studies and collaborative insights, this webinar will explore how end-to-end discovery tools can support the development of next-generation obesity therapeutics. Whether focused on early-stage target exploration or progressing candidates toward the clinic, attendees will gain practical perspectives on addressing the complexity of obesity drug discovery with greater clarity and confidence.
Key learning points:
- Understand the evolving landscape of obesity drug discovery, including emerging biological targets, therapeutic modalities, and safety considerations
- Explore the key scientific and translational challenges in developing effective and safe weight-loss therapies, from target validation to clinical candidate selection
- Learn how integrated drug discovery approaches can help accelerate and de-risk obesity therapeutic development by addressing complex mechanisms such as metabolic dysfunction, appetite regulation and energy balance
- Utilize customizable in vivo models with demonstrated proof-of-concept relevance in obesity
- Understand your molecule’s mode of action and biological context and minimize clinical failures, prior to clinical testing
Register now to secure your spot >>
SPEAKERS
Luke Oostdyk, Ph.D – Study Director at Eurofins Discovery
Dr. Luke Oostdyk is a Study Director at Eurofins Discovery and part of the LeadHunter Discovery Services team in Fremont, California. Luke completed his graduate studies in Biochemistry and Genetics at the University of Virginia where he identified novel functions and regulation of the nuclear transport factor KPNA7 and investigated the impact of epilepsy-associated mutations on receptor function and biology. After moving to industry, he spent 3 years as a scientist performing routine screening and assay development of cell-based assays for customers at Eurofins Discovery, including HTS, H2L and SAR programs. In his current role, Luke aids customers with the design and execution of studies using LeadHunter Discovery Services portfolio of cell-based assays, including both small and large molecule programs for anti-obesity therapies.
Andrew Grottick, Ph.D – Vice President In vivo Pharmacology at Eurofins Discovery
Dr Andy Grottick is an in vivo pharmacologist with more than 25 years’ experience in the drug discovery industry. He is a co-founder of Beacon Discovery (acquired by Eurofins in 2021), where he is the VP of in vivo Pharmacology. Andy has worked in both large pharma and biotech in Europe and the US where he has led multidisciplinary teams developing small molecules to treat CNS disorders. Andy currently leads a team of experts that create and run in vivo pharmacology assays across diverse therapeutic areas with a particular emphasis in metabolic and CNS diseases.
FAQs
Is the webinar free?
Yes – there is no charge to watch the webinar, either live or on-demand.
When will the webinar take place?
The webinar will take place live on 8 October 16:00 PM BST.
I’m busy. Can I watch it later?
The webinar will become available to watch on-demand shortly after the live webinar takes place.
What are the benefits of attending live?
During the live webinar, you’ll be able to ask the speakers your questions, which will then be answered during the live Q&A session towards the end of the webinar.
How long will the webinar be?
This webinar will last for up to one hour.
What do I need to watch this webinar?
All you need is a computer with an internet connection. Be sure to use headphones if in an office environment.
Do I receive a certificate?
Yes, you will receive a certificate if you attend the webinar live. The certificate will be sent with your on-demand video link.
